Transcriptomic Profiling of 39 Commonly-used Neuroblastoma Cell Lines

Overview

Journal Sci Data

Specialty Science

Date 2017 Mar 29

PMID 28350380

Citations 92

Authors

Jo Lynne Harenza

Maura A Diamond

Rebecca N Adams

Michael M Song

Heather L Davidson

Lori S Hart

Maiah H Dent

Paolo Fortina

C Patrick Reynolds

John M Maris

Affiliations

Soon will be listed here.

Abstract

Neuroblastoma cell lines are an important and cost-effective model used to study oncogenic drivers of the disease. While many of these cell lines have been previously characterized with SNP, methylation, and/or mRNA expression microarrays, there has not been an effort to comprehensively sequence these cell lines. Here, we present raw whole transcriptome data generated by RNA sequencing of 39 commonly-used neuroblastoma cell lines. These data can be used to perform differential expression analysis based on a genetic aberration or phenotype in neuroblastoma (e.g., MYCN amplification status, ALK mutation status, chromosome arm 1p, 11q and/or 17q status, sensitivity to pharmacologic perturbation). Additionally, we designed this experiment to enable structural variant and/or long-noncoding RNA analysis across these cell lines. Finally, as more DNase/ATAC and histone/transcription factor ChIP sequencing is performed in these cell lines, our RNA-Seq data will be an important complement to inform transcriptional targets as well as regulatory (enhancer or repressor) elements in neuroblastoma.

Citing Articles

Loss of ARID1A leads to a cold tumor phenotype via suppression of IFNγ signaling.

Watson P, DeVaux C, Freeman K Sci Rep. 2025; 15(1):8716.

PMID: 40082458 PMC: 11906763. DOI: 10.1038/s41598-025-91688-4.

Exploring high-throughput drug sensitivity testing in neuroblastoma cell lines and patient-derived tumor organoids in the era of precision medicine.

Langenberg K, van Hooff S, Koopmans B, Strijker J, Kholosy W, Ober K Eur J Cancer. 2025; 218:115275.

PMID: 39954414 PMC: 11884408. DOI: 10.1016/j.ejca.2025.115275.

The Venus score for the assessment of the quality and trustworthiness of biomedical datasets.

Chicco D, Fabris A, Jurman G BioData Min. 2025; 18(1):1.

PMID: 39780220 PMC: 11716409. DOI: 10.1186/s13040-024-00412-x.

Simultaneous single-nucleus RNA sequencing and single-nucleus ATAC sequencing of neuroblastoma cell lines.

Guyer R, Mueller J, Picard N, Goldstein A Sci Data. 2024; 11(1):1203.

PMID: 39511250 PMC: 11543984. DOI: 10.1038/s41597-024-04061-x.

A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma.

Hamilton A, Radaoui A, Tsang M, Martinez D, Conkrite K, Patel K Cancer Cell. 2024; 42(11):1970-1982.e7.

PMID: 39454577 PMC: 11560519. DOI: 10.1016/j.ccell.2024.10.003.

References

Nair P, McArdle L, Cornell J, Cohn S, Stallings R . High-resolution analysis of 3p deletion in neuroblastoma and differential methylation of the SEMA3B tumor suppressor gene. Cancer Genet Cytogenet. 2007; 174(2):100-10. DOI: 10.1016/j.cancergencyto.2006.11.017. View

Kang M, Smith M, Morton C, Keshelava N, Houghton P, Reynolds C . National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing. Pediatr Blood Cancer. 2010; 56(2):239-49. PMC: 3005554. DOI: 10.1002/pbc.22801. View

Bray N, Pimentel H, Melsted P, Pachter L . Near-optimal probabilistic RNA-seq quantification. Nat Biotechnol. 2016; 34(5):525-7. DOI: 10.1038/nbt.3519. View

Vandesompele J, Michels E, De Preter K, Menten B, Schramm A, Eggert A . Identification of 2 putative critical segments of 17q gain in neuroblastoma through integrative genomics. Int J Cancer. 2007; 122(5):1177-82. DOI: 10.1002/ijc.23156. View

Ciccarone V, Spengler B, MEYERS M, Biedler J, Ross R . Phenotypic diversification in human neuroblastoma cells: expression of distinct neural crest lineages. Cancer Res. 1989; 49(1):219-25. View

Li B, Dewey C . RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics. 2011; 12:323. PMC: 3163565. DOI: 10.1186/1471-2105-12-323. View

Whiteford C, Bilke S, Greer B, Chen Q, Braunschweig T, Cenacchi N . Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis. Cancer Res. 2007; 67(1):32-40. DOI: 10.1158/0008-5472.CAN-06-0610. View

Dobin A, Davis C, Schlesinger F, Drenkow J, Zaleski C, Jha S . STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2012; 29(1):15-21. PMC: 3530905. DOI: 10.1093/bioinformatics/bts635. View

Chen J, Bardes E, Aronow B, Jegga A . ToppGene Suite for gene list enrichment analysis and candidate gene prioritization. Nucleic Acids Res. 2009; 37(Web Server issue):W305-11. PMC: 2703978. DOI: 10.1093/nar/gkp427. View

10.

Decock A, Ongenaert M, Van Criekinge W, Speleman F, Vandesompele J . DNA methylation profiling of primary neuroblastoma tumors using methyl-CpG-binding domain sequencing. Sci Data. 2016; 3:160004. PMC: 4736656. DOI: 10.1038/sdata.2016.4. View

11.

Bosse K, Maris J . Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations. Cancer. 2015; 122(1):20-33. PMC: 4707066. DOI: 10.1002/cncr.29706. View

12.

Wang K, Diskin S, Zhang H, Attiyeh E, Winter C, Hou C . Integrative genomics identifies LMO1 as a neuroblastoma oncogene. Nature. 2010; 469(7329):216-20. PMC: 3320515. DOI: 10.1038/nature09609. View

13.

Murray M, STOUT A . Distinctive Characteristics of the Sympathicoblastoma Cultivated in Vitro: A Method for Prompt Diagnosis. Am J Pathol. 2009; 23(3):429-41. PMC: 1934285. View

14.

Maris J, Hogarty M, Bagatell R, Cohn S . Neuroblastoma. Lancet. 2007; 369(9579):2106-20. DOI: 10.1016/S0140-6736(07)60983-0. View

15.

Keshelava N, Davicioni E, Wan Z, Ji L, Sposto R, Triche T . Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide. J Natl Cancer Inst. 2007; 99(14):1107-19. DOI: 10.1093/jnci/djm044. View

16.

Ritchie M, Phipson B, Wu D, Hu Y, Law C, Shi W . limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015; 43(7):e47. PMC: 4402510. DOI: 10.1093/nar/gkv007. View

17.

Kim D, Langmead B, Salzberg S . HISAT: a fast spliced aligner with low memory requirements. Nat Methods. 2015; 12(4):357-60. PMC: 4655817. DOI: 10.1038/nmeth.3317. View

18.

Hart L, Rader J, Raman P, Batra V, Russell M, Tsang M . Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma. Clin Cancer Res. 2016; 23(7):1785-1796. DOI: 10.1158/1078-0432.CCR-16-1131. View

19.

Cole K, Huggins J, LaQuaglia M, Hulderman C, Russell M, Bosse K . RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma. Proc Natl Acad Sci U S A. 2011; 108(8):3336-41. PMC: 3044382. DOI: 10.1073/pnas.1012351108. View

20.

Ross R, Spengler B, Biedler J . Coordinate morphological and biochemical interconversion of human neuroblastoma cells. J Natl Cancer Inst. 1983; 71(4):741-7. View